2017-06-27 13:24:12 UTC

June 27, 2017

Genetic testing has enormous potential for identifying patients at risk for specific cancers, but we must be honest about limitations.

Genetic advances pushing the personalization of cancer prevention was a hot topic at the 2017 AGA Tech Summit, sponsored by the AGA Center for GI Innovation and Technology

In a series of presentations, experts agreed that the avenues for identifying those individuals most likely to benefit from surveillance and chemoprevention of colorectal cancer are multiplying.

However, presenter Matthew Yurgelun, MD, of Dana-Farber Cancer Institute and Harvard Medical School, Boston, expressed concern about how some of the commercially available multigene panels are being marketed and employed by both patients and physicians.

“Genetic testing often fails to give a black and white answer,” Dr. Yurgelun said. “Finding an inherited mutation in a cancer susceptibility gene carries plenty of uncertainty in many cases.” This has the potential to cause unrealistic expectations and the potential for misuse of the information, he cautioned.

“Clinicians should expect to still encounter lots of uncertainty with genetic testing, which is why it’s so critically important that such testing be done with the guidance of professional genetic counselors who can help navigate many of these uncertainties. While our technology now allows for a tremendous breadth of genetic testing options, these options have hugely expanded the number of questions and the amount of uncertainty that can be generated,” he added.

For more on this topic, read the comprehensive article in GI & Hepatology News on how genetic advances are pushing the personalization of cancer prevention . 

More on Colorectal Cancer

Principles of Gastroenterology for the NP and PA

Aug. 11, 2017

Hear from the experts as they provide you with critical updates on treating and managing patients with a variety of GI disorders.

Risk of Rectal Cancer After Colectomy for Patients With Ulcerative Colitis: A National Cohort Study

June 22, 2017

We found that the risk for rectal cancer after colectomy in patients with UC is low, in relative and absolute terms, after reconstruction with an IPAA.

Task Force Releases Updated Recommendations for Colorectal Cancer Screening

June 22, 2017

Colonoscopy and FIT tests are recommended as first line screening tests for average risk patients beginning at age 50.